A randomized study of high-dose split course radiotherapy preceded by high-dose chemotherapy versus high-dose radiotherapy only in locally advanced non-small-cell lung cancer: An EORTC Lung Cancer Cooperative Group trial

Annals of Oncology

Volumn 7, Issue 2, 1996, Pages 139-144

  Planting, A ^a   Helle, P ^a   Drings, R ^b   Dalesio, O ^c,d   Kirkpatrick, A ^c   McVie, G ^e,f   Giaccone, G ^g,h  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c EORTC DATA CENTER   (Belgium)

^d NETHERLANDS CANCER INSTITUTE   (Netherlands)

^e EORTC Lung Cancer Study Group

^f IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^g MOLINETTE HOSPITAL   (Italy)

^h VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

Advanced non small cell lung cancer; Neo adjuvant chemotherapy; Radiotherapy; Response rate; Toxicity

Indexed keywords

CISPLATIN; VINDESINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; TINNITUS; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; RADIOTHERAPY DOSAGE; SURVIVAL RATE; TREATMENT OUTCOME; VINDESINE;

EID: 0029926128     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.annonc.a010540     Document Type: Article

References (23)

1. Perez CA. Non-small cell carcinoma of the lung: Dose time parameters. Cancer Treat Symp 1985; 2: 131-42.
2. Emami B, Ferez C. Lung cancer. In Perez CA, Brady LW (eds): Principles and Practice of Radiation Oncology, 2nd edition. New York: Lippincot Company 1992; 806-36.
3. Gralla RJ, Casper ES, Kelsen DP et al. Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: A randomized trial investigating two dosage schedules. Ann Intern Med 1981; 95: 414-20.
4. Klastersky J, Sculier JP, Dabouis et al. Cisplatin versus cisplatin plus etoposide in the treatment of advanced non-small cell lung cancer. J Clin Oncol 1989; 7: 1087-92.
5. Kawahara M, Furuse K, Kodama N et al. A randomized study of cisplatin versus cisplatin plus vindesine for non-small cell lung carcinoma. Cancer 1991; 68: 714-9.
6. Donnadieu N, Paesmaus M, Sculier JP. Chemotherapy of non-small cell lung cancer according to disease extent: A meta analysis of the literature. Lung Cancer 1991; 7: 243-52.
7. TNM Classification of Malignant Tumours, UICC third edition. Geneva 1978.
8. WHO Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication No. 48. Geneva: World Health Organization 1979.
9. Cullen MH. Trials of radical radiotherapy versus chemotherapy plus radical radiotherapy in non-small cell lung cancer. Semin Oncol 1994; 21 (Suppl 4): 34-41.
10. Eagan RT, Lee RE, Frytak S et al. Thoracic radiation therapy and adriamycin/cisplatin containing chemotherapy for locally advanced non-small-cell lung cancer. Cancer Clin Trials 1981; 4: 381-8.
11. Le Chevalier T, Arriagada R, Baldeyrou P et al. Combined chemotherapy (vindesine, lomustine, cisplatin and cyclophosphamide) and radical radiotherapy in inoperable nonmetastatic squamous cell carcinoma of the lung. Cancer Treat Rep 1985; 69:469-72.
12. Tourani JM, Timsit JF, Delaisement C et al. Two cycles of cisplatin-vindesine and radiotherapy for localized non-small-cell carcinoma of the lung (stage III). Results of a prospective trial with 149 patients. Cancer 1990; 65: 1472-7.
13. Gregor A, Macbeth FR, Paul J et al. Radical radiotherapy and chemotherapy in localized inoperable non-small-cell lung cancer: A randomized trial. J Natl Cancer Inst 1993; 85: 997-9.
14. Mattson K, Holsti LR, Holsti P et al. Inoperable non-small-cell lung cancer: Radiation with or without chemotherapy. Eur J Cancer Clin Oncol 1988; 24: 477-82.
15. Le Chevalier T, Arriagada R, Qouix E et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in non-resectable noa-small-cell lung cancer: First analysis of a randomized trial in 353 patients. J Natl Cancer Inst 1991; 83: 417-23.
16. Le Chevalier T, Arriagada R, Tarayre M et al. Significant effect of adjuvant chemotherapy on survival in locally advanced non-smali-cell lung carcinoma. J Natl Cancer Inst 1992; 84: 58.
17. Crinò L, Latini P, Meacci M et al. Induction chemotherapy plus high-dose radiotherapy versus radiotherapy alone in locally advanced unresectable non-small-cell lung cancer. Ann Oncol 1993; 4: 847-51.
18. Sause WT, Scott C, Taylor S, Johnson D et al. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: Preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst 1995; 87: 198-205.
19. Dillman RO, Seagren SL, Propert KJ et al. A randomized trial of induction chemotherapy plus high dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 1990; 323: 940-5.
20. Schaake-Koning C, van den Bogaert W, Dalesio O et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 1992; 326: 524-30.
21. Thames HD, Bentzen SM, Turesson I et al. Time-dose factors in radiotherapy: A review of the human data. Radiother Oncol 1990; 19: 219-35.
22. Cox JD, Azarnia N, Byhardt RW. A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: Possible survival benefit with ≥69.6 Gy in favourable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma: Report of Radiation Therapy Oncology Group 83-11. J Clin Oncol 1990; 8: 1543-55.
23. Shaw EG, McGinnis WL, Jen JR et al. Pilot study of accelerated hyperfractionated thoracic radiation therapy plus concomitant etoposide and cisplatin chemotherapy in patients with unresectable stage III non-small-cell carcinoma of the lung. J Natl Cancer Inst 1993; 85: 321-3.